Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cholesterol/Lipid Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cholesterol/Lipid Disorders
    Atorvastatin Improves Dyslipidaemia in Patients With Coronary Heart Disease, May Be Renoprotective: Presented at Renal Week 2009 - (DGDispatch)
    Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents - (JAMA)
    TopAbstracts in Cholesterol/Lipid Disorders 10/29/2009 - (DGNews)
    Addition of Ezetimibe Helps More Elderly Achieve LDL Cholesterol Goal Than Uptitration of Atorvastatin: Presented at CCC - (DGDispatch)
    New Canadian Cholesterol-Lowering Guidelines Target Immediate-Risk Group: Presented at CCC - (DGDispatch)

    News archive

     Recent webcasts/CME - Cholesterol/Lipid Disorders
    • Optimizing Management of Dyslipidemia: Risk Assessment, Treatment Targets, and Adherence
    • Assessing Cardiovascular Risk
    • Setting Treatment Goals for Primary Prevention of Cardiovascular Disease
    • Diabetes Management - Pearls of Lipid Control
      Initiating and Monitoring Statin Therapy

      Webcasts/CME archive

       Recent cases - Cholesterol/Lipid Disorders
        There May be a Link Between Intrahepatic Cholestasis of Pregnancy and Familial Combined Hyperlipidaemia: A Case Report
        Marked Aortic Valve Stenosis Progression After Receiving Long-Term Aggressive Cholesterol-Lowering Therapy Using Low-Density Lipoprotein Apheresis in a Patient With Familial Hypercholesterolemia
        Acute Myocardial Infarction in an 18 Year Old South Indian Girl with Familial Hypercholesterolemia: A Case Report
        Eruptive Xanthomas and Acute Pancreatitis in a Patient with Hypertriglyceridemia
        Abetalipoproteinemia: Two Case Reports and a Literature Review

        Cases archive
          




        my personal edition > cholesterol/lipid disorders > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Vitamin B12 Improves Homocysteine Levels and Lipid Profiles in Patients With End-Stage Renal Disease: Presented at ISA

        By Eurona Earl Tilley

        KYOTO, JAPAN -- October 6, 2003 -- Intravenous administration of vitamin B12 reduced elevated total homocysteine (tHcy) levels, and improved the lipid profile of patients with end-stage renal disease (ESRD) who were on dialysis, according to findings presented here September 30th at the 13th International Symposium on Atherosclerosis.

        Dr. John Papadakis, department of internal medicine, University Hospital of Heraklion, Greece, who presented these findings, explained that patients with end-stage renal disease often have high serum levels of tHcy and dyslipidaemia while on dialysis.

        He and his associates evaluated the efficacy of the administration of intravenous vitamin B12 on serum tHcy, folic acid (FOL), and lipid levels in 16 women and 21 men with end-stage renal disease.

        This study was divided into 2 separate phases, each lasting 3 months. During Phase 1, patients were prescribed oral doses of folic acid 5 mg/day and vitamin B12 0.6mg/day. Through out Phase 2, participants were given intravenous doses of vitamin B12 1mg every other day in addition to folic acid 5 mg/day.

        Patients were evaluated for serum levels of tHcy, folic acid, vitamin B12, and lipid concentrations at the end of each phase. Serum levels at Phase 1 were compared to those at Phase 2.

        By the completion of the study, patients exhibited significantly lower serum tHcy (29.4 verses 21.1 mg/dL), total cholesterol (222 verses 196 mg/dL), and low-density lipoprotein cholesterol levels (139 versus 109 mg/dL). Serum high-density lipoprotein (HDL) cholesterol levels increased significantly among the participants. Mean HDL at the end of Phase 1 was 37 mg/dL, and 40 mg/dL at the end of Phase 2. There were no appreciable changes in serum concentrations of folic acid, vitamin B12, or triglycerides.

        Dr. Papadakis showed that there was a significant correlation in the data between tHcy, triglycerides, and folic acid. His results indicate that total homocysteine levels inversely correlated with serum folic acid levels, and total homocysteine levels were proportional to serum triglycerides, he concluded.


        [Study title: Effect of Intravenous Administration of Vitamin B12 on Lipids in Patients With End-Stage Renal Disease. Abstract 2P-0568]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send